Characterisation of the Immune Infiltrate and Molecular Features of Thymic Epithelial Tumors Tumors (TETs)
ConditionCancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorInstitut Curie
About this trial
The IMMUNO-TET trial aims to assess the feasibility of characterising the immune environment of TETs and the constitutional and somatic molecular profiles of patients with localised thymic epithelial tumour (TET).
Eligibility criteria
Qualifiers
Patient with suspicion of localised thymic epithelial tumour.
Age ≥ 18 years.
Treatment-naïve patient for this disease.
Patient with an indication for thymectomy and thymomectomy in one of the partner centers.
Disqualifiers
Neoadjuvant chemotherapy.
No social security affiliation.
Person under legal protection.
Other neoplasia in progress or cured within the last 3 years (except for operated carcinoma in situ).
Trial design
Treatments tested in this trial
- single arm for all patients
Treatment groups
50 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov